InvestSMART

Clever Culture Systems Limited (ASX:CC5)

ALERT: Price-sensitive ASX Announcement for CC5
Current share price for CC5 : $0.019 -0.016 (-45.71%)+
Announcement
Release
27 Aug 2025 8:16AM
Price at Release
$0.035
Full Release
download
Summary
On 5 June 2024, Clever Culture Systems Limited (CCS), a joint venture between HiberGene Diagnostics, SARSTEDT, and bioMérieux, announced the launch of its APAS Contact Plate Application. The new application is designed to automate the imaging, analysis, and interpretation of environmental contact plates in cleanroom settings, addressing critical needs in pharmaceutical manufacturing and healthcare environments for quality control and contamination monitoring. The APAS Contact Plate Application uses artificial intelligence and advanced algorithms to detect microbial growth, classify colonies, and support laboratory workflows, aiming to improve efficiency, accuracy, and regulatory compliance. The product launch demonstrates CCS’s commitment to innovation in laboratory automation and supports the broader trend toward digital transformation in clinical and manufacturing microbiology.
Key Points
  • Clever Culture Systems Limited (CCS) is a joint venture involving HiberGene Diagnostics, SARSTEDT, and bioMérieux.
  • On 5 June 2024, CCS announced the launch of the APAS Contact Plate Application.
  • The APAS Contact Plate Application automates the imaging, analysis, and interpretation of environmental contact plates.
  • The application is targeted for use in cleanroom environments, such as pharmaceutical manufacturing and healthcare settings.
  • It employs artificial intelligence to detect microbial growth and classify colonies.
  • The product aims to enhance laboratory efficiency, accuracy, and regulatory compliance.
  • The launch reinforces CCS’s position as an innovator in laboratory automation for microbiology.
  • Supports digital transformation trends in clinical and manufacturing microbiology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.